of Thanks, Jason, you us joining today. and each appreciate we
the is of to the update on three That’s our strategic foundation. progress pleased transformation. that making OraSure are strengthening first an pillars provide our We on
accelerating Next, profitable elevating core and growth. also growth, our
anticipated of stronger contracts devices flow We in QX highlights orders balance July, to these at notable are deliver and delivery orders of $XXX the quarter of we InteliSwab COVID-XX additional our revenue during for million grew million. generate to the half contracts volumes million second quarter executed when received XXXX. in of on our InteliSwab $XX to and the in few least operating under $XX than we during include, existing generated cash cash A expected
incremental part enterprise-wide as unlocked savings on We efficiency. our improved a ongoing cost operating focus of driving
key and We core basis, and sequential our our and in grow also provide are sheet, inorganic on organic and our our to innovation are enhance position partnerships we that and invigorate portfolios. for opportunities, the with portfolio externally stronger a Rigorous including delivered both internally investing additional roadmap leadership with strategic growth revenue can helping we processes and growth. balance support fuel year-over-year believe
costs. Next on
to including reductions. continue delivering we cost strengthen remain focused our in operating highly on foundation, As efficiency, greater we
The second from production expense initiatives full quarter we non-production related that headcount reductions our and as our reflects both since made the impact quarter in implemented expenses. February, are additional reduction of to a as reduce expected well costs then we’ve
re-shoring including manufacturing we consolidating automation the drive innovative to efficiencies, U.S. capacity footprints we leverage made the that quarter, our developed. of some to During operating progress have our facility to capabilities
We testing and our also and equipment manufacturing make installation progress processes Way new the continue of Opus to at facility. on
production automation OraQuick existing our to addition In of our platform.
XXXX. Way quarters, discussed phase Opus of prior completed expansion this As be to in expect we in
costs. by on and the which on deliver. to core Six Sigma a we business our methodologies in year half multiple of operating XXXX, our our automation this incorporating facilities, to across our enterprise of and generate further including second controlling operating initiatives expect training non-production of efforts the into and remain cash the breakeven Lean and flow end of target track support across leveraging consolidation XXXX, including we These additional of Overall, company efficiencies functions to
InteliSwab stronger quarter. expected COVID-XX our and $XX.X in products from we generated volumes during revenue the in were than QX million
July for orders visibility earlier, with mentioned proud purchase existing our beyond. we under I improves this partners the really potential contracts U.S. received disease our and delivery believe public of Overall, we and health readiness of additional As infectious outbreaks work in for we InteliSwab are in devices.
during In this This franchise, to CDC. year-over-year portfolio. program a and five-year funded us the core Home” providing also create our As for We momentum on that to COVID-related and start products, program, will in-home Take focuses X% could which reductions Me “Together infectious on the opportunities in earnings cash early our disease we we we’ve in excludes at-risk business, is underserved call order have QX growth the program by mentioned quarter our free revenue of we this discussed plus X% previously, our we we innovation elevate to generated growth believe and testing nationwide. from in implemented believe future populations InteliSwab the HIV the opportunities saw cost business. strong On investments basis. additional core our from grew sequentially help sustainable fund which
both a revenue segments. Moving sequential to driven by and hepatitis on a grew year-over-year domestic basis C, strengthen
be We increasing of health recognition the continue by among officials and HPV collection outreach increase need the through to testing. data surveillance to encouraged
consecutive X% sequential grew representing Shifting modest to QX, molecular of in improvement. second products, quarter sequentially revenue the
partnerships molecular believe signs that some including of positive end precision are establishing momentum of we’ve potential relationships. health. segments the commercial experienced testing in discussed new as an softness in previously, long-term enabler Fundamentally, seeing and While have continued we we
Pharmaceuticals, subsidiary very on wholly we work a of that Center, pleased on to Regeneron On to for has a collaboration the saliva focuses with are to multi-year workflow. That project and with services single-order our a our all announce RGC requirements, Genetics Inc. along front, owned its leveraging fulfillment device discovery in-house kitting genomics. DNA and functional origin collection collection remodel chosen Regeneron gene early
our organization collection to part understand IVI first burden a we our in make We as Vaccine is girls safe, continue Colli-Pee for efforts an papillomavirus, help utilize a research will development effective, study agreement portfolio, HPV volumetric health. women International commercial and of with income International the discover, study to Colli-Pee. intervention, research an lower urine and global the Also, health The recently vaccines Institute deliver to clinical with in implementation The low to of the progress greatest product affordable human and inform molecular have that and void among of impact. and and for Vaccine signed mission with Institute middle and kits develop, prioritization countries. potential public
patient’s settings, void urine vaccination the patient can and We collection to provide screening, through powerful to non-invasive a believe Regardless wherever how our collection is strategies. sample professional power healthcare to that are. can the potential with help connects first familiarity HPV in fundamental that or with the treatment that approach methods effortless patients to sample insights healthcare consumers has they transform geographical delivery of at-home and care offerings proximity shift
noninvasive the innovation. committed the Colli-Pee potential to an emerging to These urine for improved an people patient Microbiome another use, solution is OraSure ongoing of is prior as and demonstrate device, to globe. delivering around contribute experience precision health to value collection easy has self-sampling and studies science evidence-based affordable with that
advance leverage of work in customers services the space, power the consumer collection Our in clinical the are done note used pioneering devices the to to and new of developing microbiome is to applications research our therapeutics. direct microbiome by and biotech
of nutrition a included VOWST, company FDA microbiome One Seres, the recurrent jointly program only recurrence microbiota-based and approval leader such FDA therapeutics Phase III treatment administered customer science Science, diff that and antibacterial of announced the is Nestle of C. difficile orally approval for in ECOSPOR developing or C. infection. the therapeutic, Health CDI first commercial-stage prevent in have by supported novel Seres and ECOSPOR infection VOWST development studies. a The a Therapeutics. IV of the robust adults following was to X
option provided On growth sequencing internal the and services roadmap, as addition innovation for our approval important as to strengthening of during series new investments our in partnerships portfolio, we year. the to this product see development last sheets Diversigen oral subsidiary the microbiome C. make of investments, OraSure’s and infection. diff profitable progress acquisitions balance current in initiatives products this on continue through to for for our our pleased to by pipeline, enabled FDA accelerate external potential well are studies the our treatment
diagnostics that We portfolio are an have expand infectious respiratory disease, areas have and in where of prior such working we our assays we on in influenza, opportunities health. to in discussed sexual existing as quarters strong capabilities
expect more share on this We to these year. opportunities later
few partners such initiated a Molecular, as quarters, in to past broad have Quest specific counseling as In new the new launching over cases such and Diagnostics, disease precision across well range those their in see progress testing testing. services, of [indiscernible] It’s genetic Grifols our use consumer health. and collaborations offerings as as we great shared
Two, our they the segment track expanded partner enable. the patient the due processes of our be of well several precision and Overall, successfully and execution, and quality to we to differentiators. regulatory for record expansion. collaborating important to access navigating and OraSure our with believe reach complex help is choice offerings our One, partners of three, power delivery consistency and the approval and health positioned reliability of
and I’d that, Ken With financial guidance. to over to like to turn discuss our the results call
